Giant prolactinomas presenting as scull base tumors

被引:25
作者
Minniti, G
Jaffrain-Rea, ML
Santoro, A
Esposito, V
Ferrante, L
Delfini, R
Cantore, G
机构
[1] Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy
[2] INM IRCCS Neuromed, Pozzilli, Italy
[3] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
来源
SURGICAL NEUROLOGY | 2002年 / 57卷 / 02期
关键词
prolactinoma; skull base; cabergoline; dopamine agonist;
D O I
10.1016/S0090-3019(01)00697-8
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND Prolactinomas invading the skull base are rare, and could easily be confused with skull base tumors of nonpituitary origin. CASE DESCRIPTION We report a series of 4 cases of giant prolactinomas invading the skull base and presenting with atypical symptoms. Case 1 presented with a short history of headache and nasal obstruction. Case 2 presented with progressive hypoacusia, dizziness, and ophthalmoplegia. In Case 3, the patient developed rapid progressive visual failure and psychiatric symptoms. Case 4 presented with a 1-year history of headache and retrorbital pain. The diagnosis of prolactinoma was made on the basis of tumor immunohistochemistry and/or high plasma prolactin levels (range from 650-6,500 ng/mL). Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. CONCLUSION Prolactin levels should be measured in all large skull base tumors involving the pituitary region before any surgery or inappropriate radiotherapy is performed. (C) 2002 by Elsevier Science Inc.
引用
收藏
页码:99 / 103
页数:5
相关论文
共 23 条
[1]   DOPAMINE AGONISTS AND PITUITARY-TUMOR SHRINKAGE [J].
BEVAN, JS ;
WEBSTER, J ;
BURKE, CW ;
SCANLON, MF .
ENDOCRINE REVIEWS, 1992, 13 (02) :220-240
[2]  
Buchfelder M, 1996, Acta Neurochir Suppl, V65, P18
[3]   PROLACTINOMAS IN MEN MASQUERADING AS INVASIVE SKULL BASE TUMORS [J].
COOK, RJ ;
UTTLEY, D ;
WILKINS, PR ;
ARCHER, DJ ;
BELL, BA .
BRITISH JOURNAL OF NEUROSURGERY, 1994, 8 (01) :51-55
[4]   Late development of resistance to bromocriptine in a patient with macroprolactinoma [J].
Delgrange, E ;
Crabbé, J ;
Donckier, J .
HORMONE RESEARCH, 1998, 49 (05) :250-253
[5]   Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine [J].
Delgrange, E ;
Maiter, D ;
Donckier, J .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1996, 134 (04) :454-456
[6]   SHOULD DOPAMINE AGONIST TREATMENT FOR PROLACTINOMAS BE LIFELONG [J].
FAGLIA, G .
CLINICAL ENDOCRINOLOGY, 1991, 34 (03) :173-174
[7]   LONG-LASTING PROLACTIN-LOWERING EFFECT OF CABERGOLINE, A NEW DOPAMINE AGONIST, IN HYPERPROLACTINEMIC PATIENTS [J].
FERRARI, C ;
BARBIERI, C ;
CALDARA, R ;
MUCCI, M ;
CODECASA, F ;
PARACCHI, A ;
ROMANO, C ;
BOGHEN, M ;
DUBINI, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :941-945
[8]   SUBARACHNOID DISSEMINATION OF A PITUITARY-ADENOMA [J].
KUROKI, M ;
TANAKA, R ;
YOKOYAMA, M ;
SHIMBO, Y ;
IKUTA, F .
SURGICAL NEUROLOGY, 1987, 28 (01) :71-76
[9]  
LANDOLT AM, 1975, ACTA NEUROCHIR SUPP, V2, P94
[10]   CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas [J].
Leong, KS ;
Foy, PM ;
Swift, AC ;
Atkin, SL ;
Hadden, DR ;
MacFarlane, IA .
CLINICAL ENDOCRINOLOGY, 2000, 52 (01) :43-49